Biocure Technology Inc. CUREX
CNSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -- | -26.62% | -80.18% | -75.59% | -80.20% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -26.62% | -80.18% | -75.59% | -80.20% |
| Operating Income | -- | 26.62% | 80.18% | 75.59% | 80.20% |
| Income Before Tax | -- | -401.31% | 60.68% | 93.12% | 94.20% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | -401.31% | 60.68% | 93.12% | 94.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -401.31% | 60.68% | 93.18% | 94.24% |
| EBIT | -- | 26.62% | 80.18% | 75.59% | 80.20% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -- | -174.69% | 72.57% | 94.50% | 95.22% |
| Normalized Basic EPS | -- | 45.63% | 72.97% | 75.05% | 79.92% |
| EPS Diluted | -- | -174.69% | 72.57% | 94.50% | 95.22% |
| Normalized Diluted EPS | -- | 45.63% | 72.97% | 75.05% | 79.92% |
| Average Basic Shares Outstanding | -- | -39.17% | -47.82% | -55.96% | 186.44% |
| Average Diluted Shares Outstanding | -- | -39.17% | -47.82% | -55.96% | 186.44% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |